ArticleJournal of oral and maxillofacial pathology : JOMFP2025
Decoding myoepithelioma: Highlighting diagnostic dilemmas through a series of rare cases.
Article in Journal of oral and maxillofacial pathology : JOMFP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myoepitheliomas are exceedingly rare neoplasms of the salivary glands. Minor salivary gland neoplasms most frequently occur in the palate (hard palate), followed by the lips, oral mucosa, and tongue/floor of the mouth. Additionally, less prevalent locations encompass the retromolar area, pharynx, nasal cavity, paranasal sinuses, and larynx. The lack of distinctive cytologic features and bland morphology in both benign and malignant myoepitheliomas necessitates the use of histopathology and immunohistochemistry for accurate diagnosis. Hence, here, we report a series of three cases, including two benign and one malignant myoepithelioma, stressing the significance of the above-mentioned techniques for efficient diagnosis and management. This rare case series comprises many salivary gland myoepithelial neoplasms. Examples include the cystic plasmacytoid and clear cell myoepithelioma and low-grade myoepithelial carcinoma with parenchymal invasion. Immunohistochemical myoepithelial markers include vimentin, smooth muscle antigen, S 100, and p63. All of our patients had a positive p63. Myoepithelioma is diagnosed by biopsy because many tumours have similar clinical and radiological characteristics. They rarely reoccur, improving prognosis. Malignant myoepitheliomas may require wide local excision with clean margins. Regular follow-up is recommended. Myoepitheliomas are rare salivary gland tumours. Myoepithelioma should be suspected in slow-growing, well-defined salivary gland masses with variable post-contrast enhancement on CT images. Histopathology and immunohistochemistry are the best myoepithelioma diagnostic methods. Malignant myoepithelioma must be ruled out by thorough invasion testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.